Literature DB >> 2785420

Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow.

M A King1, D S Nelson.   

Abstract

Tumor cells from six patients with immunoglobulin G (IgG) multiple myeloma were analyzed for surface antigens, cytoplasmic paraprotein, morphology, and response to various culture conditions. The tumor marker was the paraprotein idiotype. Low numbers of tumor cells were found in the blood of most of the patients. In some patients, the circulating tumor cells were solely B lymphocytes, whereas in other patients, they were lymphoid, lymphoplasmacytoid, and plasmacytoid. Dual surface antigen analysis of blood and bone marrow cells confirmed that the tumor may be composed of a spectrum of cell types. Thus, cells may range from surface-idiotype+,CD19+,CD20+, PCA-1-,cytoplasmic-idiotype- lymphocytes, to CD19-,PCA-1+,cytoplasmic-idiotype+ plasma cells that are surface-idiotype- or weakly surface-idiotype+. In one patient, some of the tumor cells co-expressed surface idiotype and CD10. The tumor B lymphocytes were activated in vitro to synthesize paraprotein by pokeweed mitogen (PWM), and by low molecular weight B cell growth factor (BCGF). In contrast, spontaneous synthesis of paraprotein by more mature tumor cells was inhibited by agents that also inhibit nonmyeloma plasma cells. These agents included PWM, gamma interferon, and phorbol ester. The results demonstrate that in multiple myeloma there exist different tumor cell types that are similar, by a variety of criteria, to normal B lineage cells at different stages of differentiation. Thus, further evidence is provided for the hypothesis of myeloma cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785420

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Authors:  R Leo; M Boeker; D Peest; R Hein; R Bartl; J E Gessner; J Selbach; G Wacker; H Deicher
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

2.  CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

Authors:  M Zandecki; T Facon; F Bernardi; V Izydorczyk; L Dupond; M François; R Reade; T Iaru; F Bauters; A Cosson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

Review 3.  Multiple myeloma cancer stem cells.

Authors:  Carol Ann Huff; William Matsui
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

4.  Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications.

Authors:  R Luque; J A Brieva; A Moreno; A Manzanal; L Escribano; J Villarrubia; J L Velasco; J López-Jiménez; C Cerveró; M J Otero; J Martínez; C Bellas; E Roldán
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

5.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

6.  Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.

Authors:  Marie-Christine Kyrtsonis; Vassiliki Bartzis; Xenophon Papanikolaou; Efstathios Koulieris; George Georgiou; Maria Dimou; Tatiana Tzenou; Panayiotis Panayiotidis
Journal:  Appl Clin Genet       Date:  2010-07-28

7.  The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.

Authors:  D Billadeau; G Ahmann; P Greipp; B Van Ness
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

8.  Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization.

Authors:  Ying Hu; Wenming Chen; Shilun Chen; Zhongxia Huang
Journal:  Onco Targets Ther       Date:  2016-03-03       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.